p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer
Open Access
- 12 June 2012
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 21 (6), 793-806
- https://doi.org/10.1016/j.ccr.2012.04.027
Abstract
No abstract availableThis publication has 62 references indexed in Scilit:
- Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stabilityProceedings of the National Academy of Sciences of the United States of America, 2011
- p53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesisOncogene, 2009
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancerBreast Cancer Research and Treatment, 2009
- Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7Cell, 2008
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progressionInternational Journal of Cancer, 2005
- The role of apoptosis in cancer development and treatment responseNature Reviews Cancer, 2005
- Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in miceOncogene, 2004
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993